Results 311 to 320 of about 860,286 (378)

Renin-Angiotensin System Inhibition in Patients With Myocardial Injury Complicating Transcatheter Aortic Valve Replacement. [PDF]

JACC Adv
Tomii D, Heg D, Lanz J, Nakase M, Samim D, Stortecky S, Reineke D, Windecker S, Pilgrim T.   +8 more
europepmc   +1 more source

Targeting Regulation of Macrophage to Treat Metabolic Disease: Role of Phytochemicals

Cell Proliferation, EarlyView.
One‐third of the world's population is affected by metabolic syndrome. Complicated pathogenesis and limited drugs cause the growing prevalence of metabolic syndrome. Macrophage‐mediated metaflammation is closely associated with the development of metabolic syndrome. The role of phytochemicals targeting macrophages in the treatment of metabolic syndrome
Zeting Ye, Yanlin Li, Xiaolin Yang, Chenglin Li, Rui Yu, Guangjuan Zheng, Zuqing Su   +6 more
wiley   +1 more source

Renin-angiotensin system inhibitor use and risk of Parkinson's disease: a meta-analysis. [PDF]

Acta Neurol Belg
Xu TX, Jiang HY, Yang ZY.
europepmc   +1 more source

Use of renin-angiotensin system blockers and posttraumatic stress disorder risk in the UK Biobank: a retrospective cohort study. [PDF]

BMC Med
Kang S, Kim J, Yang JS, Jeon YJ, Lee HH, Suglia SF, Tsai AC, Kang JI, Jung SJ.   +8 more
europepmc   +1 more source

Mechanisms of diabetic cardiomyopathy: Focus on inflammation

Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2326-2338, May 2025.
Abstract Purpose of Review Type 2 diabetes (T2D) significantly increases the risk of heart failure (HF), either through the progression of coronary artery disease (CAD) or through direct myocardial alterations, termed diabetic cardiomyopathy. This review examines key pathophysiological mechanisms underlying diabetic cardiomyopathy, focusing on the role
Myriam Bellemare, Liane Bourcier, Josep Iglesies‐Grau, Jacinthe Boulet, Eileen O'Meara, Nadia Bouabdallaoui   +5 more
wiley   +1 more source

Renin-angiotensin system inhibitors and risk of hepatocellular carcinoma among patients with hepatitis B virus infection. [PDF]

CMAJ
Chen R, Zhou S, Liu J, Li L, Su L, Li Y, Fang C, Zhang X, Luo F, Gao Q, Lin Y, Guo Z, Cao L, Xu X, Nie S.   +14 more
europepmc   +1 more source

Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial

Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2473-2484, May 2025.
Abstract Aims Anti‐vascular endothelial growth factor (VEGF) therapy is the standard treatment for diabetic macular oedema (DMO); however, unmet needs remain. This study aimed to assess the effectiveness of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in treating DMO.
Ryoichi Ishibashi, Yoko Takatsuna, Masaya Koshizaka, Tomoaki Tatsumi, Sho Takahashi, Kengo Nagashima, Ko Ishikawa, Tomomi Kaiho, Noriko Asaumi, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote, The COMET Trial investigators   +12 more
wiley   +1 more source

Renin Is Essential for Angiotensin II Formation in the Brain

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
André F. Rodrigues, Oliver Domenig, Ingrid M. Garrelds, A.H. Jan Danser, Natalia Alenina, Marko Poglitsch, Michael Bader   +6 more
doaj   +1 more source

Neuronal ACE1 knockout disrupts the hippocampal renin angiotensin system leading to memory impairment and vascular loss in normal aging. [PDF]

Neurobiol Dis
Jeon S, Salvo MA, Alia AO, Popovic J, Zagardo M, Chandra S, Nassan M, Gate D, Vassar R, Cuddy LK.   +9 more
europepmc   +1 more source

Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type‐2 diabetes and chronic kidney disease: DPV registry study

Diabetes, Obesity and Metabolism, Volume 27, Issue 5, Page 2485-2494, May 2025.
Abstract Aims Managing type‐2 diabetes (T2D) in chronic kidney disease (CKD) patients requires consideration of kidney function, and many drugs have not been investigated thoroughly. Clinical studies have demonstrated Glargine U300 (Gla‐300) supports achievement of adequate glycemic control at low hypoglycemia risk.
Anjaly Vijayan, Stefanie Lanzinger, Nicole Forestier, Gregor Hess, Marcus Rottmann, Frank J. Wosch, Jochen Seufert, Reinhard W. Holl, Peter Bramlage, for the DPV   +9 more
wiley   +1 more source